Clinical data for patients with β-thalassemia and their UDs
. | HLA-DPB1* . | . | . | ||
---|---|---|---|---|---|
. | Matched and permissive . | Nonpermissive . | . | ||
. | . | HvG direction . | GvH direction . | ||
No. of patients | 45 | 17 | 10 | ||
Sex of donor/recipient, no. cases | |||||
Female/male | 11 | 3 | 3 | ||
Other combinations | 34 | 14 | 7 | ||
Median age, y (range) | |||||
Donor | 32 (21-44) | 33 (19-48) | 36 (20-52) | ||
Patient | 15 (6-24) | 15 (1.5-37) | 14 (1.5-26) | ||
Class†, no. | |||||
1 | 14 | 5 | 2 | ||
2 | 12 | 6 | 2 | ||
3 | 19 | 6 | 6 | ||
Donor/recipient HCMV serology, no. cases | |||||
Negative/negative | 2 | 4 | 1 | ||
Other combinations | 43 | 13 | 9 | ||
Median cell dose, × 108/kg (range) | 3.8 (2-8.3) | 4.8 (0.2-15) | 4.5 (0.3-12) | ||
Conditioning, no. | |||||
BU-CY | 11 | 5 | 2 | ||
BU-TT-CY | 21 | 9 | 6 | ||
BU-TT-FLU-ATG | 13 | 3 | 2 | ||
Rejection, no. | 2 | 4 | 1 | ||
aGvHD II–IV‡, no. | 14 | 8 | 4 | ||
OS, no. | 37 | 13 | 7 | ||
TFS, no. | 35 | 10 | 6 |
. | HLA-DPB1* . | . | . | ||
---|---|---|---|---|---|
. | Matched and permissive . | Nonpermissive . | . | ||
. | . | HvG direction . | GvH direction . | ||
No. of patients | 45 | 17 | 10 | ||
Sex of donor/recipient, no. cases | |||||
Female/male | 11 | 3 | 3 | ||
Other combinations | 34 | 14 | 7 | ||
Median age, y (range) | |||||
Donor | 32 (21-44) | 33 (19-48) | 36 (20-52) | ||
Patient | 15 (6-24) | 15 (1.5-37) | 14 (1.5-26) | ||
Class†, no. | |||||
1 | 14 | 5 | 2 | ||
2 | 12 | 6 | 2 | ||
3 | 19 | 6 | 6 | ||
Donor/recipient HCMV serology, no. cases | |||||
Negative/negative | 2 | 4 | 1 | ||
Other combinations | 43 | 13 | 9 | ||
Median cell dose, × 108/kg (range) | 3.8 (2-8.3) | 4.8 (0.2-15) | 4.5 (0.3-12) | ||
Conditioning, no. | |||||
BU-CY | 11 | 5 | 2 | ||
BU-TT-CY | 21 | 9 | 6 | ||
BU-TT-FLU-ATG | 13 | 3 | 2 | ||
Rejection, no. | 2 | 4 | 1 | ||
aGvHD II–IV‡, no. | 14 | 8 | 4 | ||
OS, no. | 37 | 13 | 7 | ||
TFS, no. | 35 | 10 | 6 |